信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

休市中 05-09 16:08:07

52.400

+0.700

+1.35%

最高53.050	最低50.550	成交量941.26万
今开51.000	昨收51.700	日振幅4.84%
总市值864.60亿	流通市值864.60亿	总股本16.50亿
成交额4.91亿	换手率0.57%	流通股本16.50亿
市净率6.13	ROE-0.74%	每股收益-0.06
52周最高56.100	52周最低28.650	市盈率-838.82
股息0.00	股息收益率0.00	ROA-0.82%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":52.4,"timestamp":1746778087014,"preClose":51.7,"halted":0,"volume":9412603,"delay":0,"floatShares":1650000000,"shares":1650000000,"eps":-0.06246867373497726,"marketStatus":"休市中","change":0.7,"latestTime":"05-09 16:08:07","open":51,"high":53.05,"low":50.55,"amount":490772650,"amplitude":0.048356,"askPrice":52.45,"askSize":79000,"bidPrice":52.35,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.06446050328653107,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747013400000},"marketStatusCode":7,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":51.7,"openAndCloseTimeList":[[1746754200000,1746763200000],[1746766800000,1746777600000]],"volumeRatio":0.5392863006461601,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.6227,"impliedVolPercentile":0.8443},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2534012521","title":"信达生物05月09日获主力加仓656.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534012521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534012521?lang=zh_cn&edition=full","pubTime":"2025-05-09 16:15","pubTimestamp":1746778536,"startTime":"0","endTime":"0","summary":"05月09日, 信达生物股价涨1.35%，报收52.40元，成交金额4.9亿元，换手率0.57%，振幅4.84%，量比0.54。信达生物今日主力资金净流入656.9万元，上一交易日主力净流入2795.8万元。该股近5个交易日下跌2.23%，主力资金累计净流入6308.2万元；近20日主力资金累计净流入4.2亿元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509175618a477fae3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509175618a477fae3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2488822045.USD","01801","LU1969619763.USD","BK1583","LU2328871848.SGD","BK1589"],"gpt_icon":0},{"id":"2533254629","title":"独家：信达生物重磅药品降价25%，确认参加医保谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2533254629","media":"健识局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533254629?lang=zh_cn&edition=full","pubTime":"2025-05-08 14:15","pubTimestamp":1746684956,"startTime":"0","endTime":"0","summary":"图源：豆包5月6日，江苏省公共资源交易中心显示：信达生物的氟泽雷塞片已从24900元一瓶降至18600元，降幅达25.3%。眼下正是国谈前夕，历年国谈前都会有一波药企主动下调药品价格，为医保谈判做准备。5月7日，信达生物向健识局确认：氟泽雷塞片会参与今年的国家医保目录调整。不过，艾力斯已经明确表态：会全力推进戈来雷塞片尽快获批上市，努力争取参加今年的医保谈判工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508142122a476444d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508142122a476444d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","LU2328871848.SGD","BK1589","LU2488822045.USD","BK1583","BK1161","LU1969619763.USD"],"gpt_icon":0},{"id":"2533160479","title":"【券商聚焦】中泰国际调整信达生物(01801)评级至“增持” 指其首季产品销售收入略超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2533160479","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533160479?lang=zh_cn&edition=full","pubTime":"2025-05-08 09:48","pubTimestamp":1746668898,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际研报指，信达生物 一季度产品销售收入同比增加超40%至超24亿元，主因：1）肿瘤药达伯舒的销售收入维持快速扩张，一季度销售收入同比增加17.8%至1.38亿美元；2）公司一季度新增获批四款新药，包括肿瘤领域的达伯乐、奥壹新、捷帕力与甲状腺眼病药物信必敏，导致公司获批的产品数量增加至15款。综合以上情况，公司一季度产品销售收入略超预期。目标价上调至60.00港元，由于股价近期上涨，评级调整至“增持”。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1958306","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"gpt_icon":0},{"id":"2533626771","title":"海通国际：维持信达生物(01801)“优于大市”评级 目标价62.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533626771","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533626771?lang=zh_cn&edition=full","pubTime":"2025-05-07 14:06","pubTimestamp":1746597992,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海通国际发布研报称，结合信达生物2025Q1年营收情况、该行调整盈利预测及估值模型。海通国际主要观点如下：事件：公司发布2025年Q1业绩，实现产品营收超24亿元。产品营收维持高速增长，进一步向27年200亿元收入目标靠近根据公司业绩公告，24年Q4产品营收约为21.2亿元。临床前研究中，IBI3020在多种荷瘤药理学模型中展现出了良好抗肿瘤活性，并具有旁观者杀伤效应;且IBI3020安全性特征良好，整体安全性可控。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801"],"gpt_icon":0},{"id":"2533664505","title":"大华继显：“买入”名单新增阿里巴巴-W(09988)、信达生物(01801)、双环传动(002472.SZ)及携程-S(09961)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533664505","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533664505?lang=zh_cn&edition=full","pubTime":"2025-05-06 17:30","pubTimestamp":1746523830,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大华继显发布研报称，恒生指数和MSCI中国指数在4月分别下跌4.3%和5.2%，受4月初特朗普关税宣布以及对全球衰退可能的担忧推动。由于持续的外部不确定性，该行将维持对国内政策受益者和防御性行业的配置。大华继显的“买入”名单新增阿里巴巴-W、信达生物、双环传动和携程-S，并对华润置地和健倍苗苗进行获利了结。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4527","LU1917777945.USD","LU0029874905.USD","09961","LU0588546209.SGD","002472","HK0000306701.USD","LU0011963245.USD","IE0003851619.USD","LU0672654166.SGD","LU0051755006.USD","LU0396098781.USD","LU0370786039.SGD","LU1282651121.HKD","BK1164","IE00B543WZ88.USD","BK1191","BK4587","HK0000320223.HKD","LU0348783662.USD","LU1211504680.USD","LU1813983027.USD","01109","01801","BK1521","IE00BZ08YT58.USD","LU0577902371.SGD","TCOM","HBBD.SI","LU0828237510.HKD","IE00B8HQ1Z84.USD","LU0588545490.SGD","LU1267930227.SGD","SG9999006514.SGD","LU0594300419.USD","LU0278937759.USD","09988","89988","BK1591","LU1303224171.USD","LU1366334651.USD","BK4220","LU0320764599.SGD","LU1688375341.USD","02161","LU0823426308.USD","LU0651947912.USD","SG9999002828.SGD","BK0259"],"gpt_icon":0},{"id":"2533261683","title":"可每12周一次！信达生物双靶点新药2期临床完整数据公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2533261683","media":"医药时间","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533261683?lang=zh_cn&edition=full","pubTime":"2025-05-06 17:20","pubTimestamp":1746523239,"startTime":"0","endTime":"0","summary":"本次公布的摘要标题为：IBI302在新生血管性年龄相关性黄斑变性受试者中长间隔给药的2期临床研究。根据信达生物新闻稿介绍，对于新生血管性年龄相关性黄斑变性的治疗，当前药物研发聚焦于多靶点治疗策略及延长间隔给药，旨在通过减少治疗频次降低患者治疗负担。此外，IBI302组中初步观察到其延缓黄斑萎缩发生的潜力。该创新疗法有望早日完成确证性注册临床研究，为更多nAMD患者提供更优的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506173816a473d0d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506173816a473d0d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2328871848.SGD","LU2488822045.USD","BK1161","BK1583","01801","BK1589"],"gpt_icon":0},{"id":"2533574131","title":"【券商聚焦】东吴证券维持信达生物(01801)“买入”评级 指伴随产品放量和费用控制 公司有望持续盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2533574131","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533574131?lang=zh_cn&edition=full","pubTime":"2025-05-06 16:55","pubTimestamp":1746521753,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券发研指，信达生物 25Q1产品收入超24亿元，同比增长40%+。主要得益于：1、信迪利单抗等主要产品依然保持快速的增长态势；2、新产品收入贡献加速提升：托莱西单抗和奥雷巴替尼新适应证新进入国家医保目录，以及甲状腺眼病治疗药物替妥尤单抗在今年3月获批上市，为增长贡献新驱动力。该行预计随着产品组合的不断放量和费用的有效控制，信达有望持续盈利，国际化进程加速，维持“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1958182","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","601555"],"gpt_icon":0},{"id":"2533506642","title":"消费医疗的春天还早，但有人还是吃到红利","url":"https://stock-news.laohu8.com/highlight/detail?id=2533506642","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533506642?lang=zh_cn&edition=full","pubTime":"2025-05-06 16:37","pubTimestamp":1746520624,"startTime":"0","endTime":"0","summary":"2024年，医疗行业继续在复杂的市场变化中找寻自身路径。一方面，大健康的热潮一度让市场认为消费医疗将成为趋势新红利。但纵览相关赛道的上市公司年报，这种红利的兑现远未到来。另一方面，“卷”仍是国内医疗行业避开不了的关键词。最后，当下的医疗行业是否没有细分赛道处于红利期，答案是否定的。疫苗行业的高光时刻，终结于疫情结束。血液制品的赛道，各家都实现增长，但增速各有不同。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/256521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU1969619763.USD","BK1574","LU2328871848.SGD","LU2488822045.USD","BK1161","BK1583","06978","01801","BK1589"],"gpt_icon":0},{"id":"2533463235","title":"医药生物行业周报：业绩修复周期开启，双主线聚焦“创新药+AI医疗”","url":"https://stock-news.laohu8.com/highlight/detail?id=2533463235","media":"信达证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533463235?lang=zh_cn&edition=full","pubTime":"2025-05-06 16:08","pubTimestamp":1746518928,"startTime":"0","endTime":"0","summary":"本期内容提要:市场表现：上周医药生物板块收益率为0.49%，板块相对沪深300收益率为0.93%，在31个一级子行业指数中涨跌幅排名第9。我们认为随着医疗整顿负面影响逐步消化，院内市场有望逐步恢复，叠加院外消费医疗需求复苏，25Q2医药板块有望整体迎来业绩修复，建议重点关注复苏逻辑及经营改善逻辑的板块和个股，此外，随着降息降准预期提升，创新药+AI医疗主题仍有望成为下一阶段的进攻方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506161143975067aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506161143975067aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0516423174.USD","BK1576","LU0516422440.USD","LU0181495838.USD","LU2039709279.SGD","LU0327786744.USD","LU1242518857.USD","LU0708995583.HKD","BK1589","LU0823426480.USD","LU0051755006.USD","LU0856984785.SGD","LU1794554557.SGD","SG9999002562.SGD","LU0979878070.USD","LU0320764599.SGD","LU0572944931.SGD","LU0359202008.SGD","LU0819121731.USD","BK1574","BK1141","LU0052750758.USD","09926","LU0516422952.EUR","LU0348825331.USD","LU0588546209.SGD","SG9999002463.SGD","LU0039217434.USD","01801","02269","IE00B0JY6N72.USD","LU0307460666.USD","06978","LU1242518931.SGD","LU0326950275.SGD","LU0516423091.SGD","LU0043850808.USD","LU0417516738.SGD","BK1161","LU0456827905.SGD","LU0823426308.USD","BK1610","LU0348735423.USD","LU0140636845.USD","LU1880383366.USD","LU0359201612.USD","LU0417516902.SGD","LU1688375341.USD","LU0516422366.SGD","LU0456846285.SGD","LU1720050803.USD","BK1521"],"gpt_icon":0},{"id":"2533959475","title":"中金：维持信达生物(01801)“跑赢行业”评级 升目标价至66港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533959475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533959475?lang=zh_cn&edition=full","pubTime":"2025-05-06 09:27","pubTimestamp":1746494822,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持信达生物2025年/2026年归母净利润预测4.72亿元/12.98亿元不变。该行维持跑赢行业评级。考虑到公司下一代重磅产品 IBI363 PoC数据成熟及ADC管线进展，有望解锁更广阔的全球商业化空间，基于DCF模型，该行上调目标价12.2%至66港币，较当前股价有20.2%的上行空间。截至2025年4月，公司有15款产品获批上市，3款正在审评中心，4个新药分子进入3期或者关键性临床研究。该行认为公司正完善“IO+ADC”创新技术平台的全方位布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801"],"gpt_icon":0},{"id":"2533596248","title":"信达生物全球首创抗VEGF-补体双靶融合蛋白","url":"https://stock-news.laohu8.com/highlight/detail?id=2533596248","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533596248?lang=zh_cn&edition=full","pubTime":"2025-05-06 08:00","pubTimestamp":1746489600,"startTime":"0","endTime":"0","summary":"值得关注的是，全球首个创新型双靶点分子IBI302II期数据显示其高剂量组达到主要研究终点，一年期最佳矫正视力较基线提升10个字母左右，超过80%的受试者能够维持长达12周及以上的给药间隔。\" 关于依莫芙普 依莫芙普是信达生物拥有全球知识产权的一种双特异性重组全人源融合蛋白，研发代号：IBI302。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总价值36亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4679597_ZH79597_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","IVBIY","LU2488822045.USD","LU1969619763.USD","BK1589","LU2328871848.SGD","01801","BK1583","BK4139"],"gpt_icon":0},{"id":"2532362889","title":"港股生物科技板年内大涨 医药主题基金表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2532362889","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532362889?lang=zh_cn&edition=full","pubTime":"2025-05-04 08:40","pubTimestamp":1746319245,"startTime":"0","endTime":"0","summary":"多只细分领域龙头股股价创新高，荣昌生物年内涨幅达到187.5%，三生制药、康宁杰瑞制药-B等涨幅超过120%，信达生物、百济神州、诺诚健华等涨幅超过40%。生物科技板块的强劲表现带动相关主题基金收益飙升。据Wind数据，截至4月30日，在今年来收益率排名前20的权益基金中，9只为医药主题基金，收益率均在40%以上。有业内人士表示，2025年或将成为中国创新药行业的关键转折点。中期来看，2025年至2028年将是中国创新药企业集体步入盈利期的关键阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250504084143a6d27d9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250504084143a6d27d9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1589","LU2488822045.USD","BK1161","HSCEI","LU2328871848.SGD","LU1969619763.USD","HSTECH","01801","09969"],"gpt_icon":1},{"id":"2532681814","title":"淡马锡控股公司减持信达生物(01801)304.85万股 每股作价约51.98港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532681814","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532681814?lang=zh_cn&edition=full","pubTime":"2025-05-02 18:45","pubTimestamp":1746182752,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，4月25日，淡马锡控股公司减持信达生物(01801)304.85万股，每股作价51.9847港元，总金额约为1.58亿港元。减持后最新持股数目约为1.15亿股，最新持股比例为6.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801","LU2328871848.SGD","BK1589","LU2488822045.USD","BK1583","BK1161","LU1969619763.USD"],"gpt_icon":0},{"id":"2532868868","title":"大摩：暂维持信达生物(01801)目标价67港元 评级“增持”","url":"https://stock-news.laohu8.com/highlight/detail?id=2532868868","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532868868?lang=zh_cn&edition=full","pubTime":"2025-05-02 11:17","pubTimestamp":1746155834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，预期信达生物随后几个季度的商业市场动态信息将预示国内新型降血糖治疗药物GLP1的供需动态。暂维持目标价67港元及“增持”评级。据报道，集团旗下研发的辛迪利单抗注射液 第一季销售额增18%，大摩认为这表明信达生物投资组合中的其他产品将实现更高的增长，同时仍高于2025年14%的年增预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801"],"gpt_icon":0},{"id":"2532857460","title":"恒生生物科技指数盘中涨超1%，药明康德涨超5%，药明生物、京东健康、信达生物纷纷走强。","url":"https://stock-news.laohu8.com/highlight/detail?id=2532857460","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532857460?lang=zh_cn&edition=full","pubTime":"2025-05-02 10:47","pubTimestamp":1746154049,"startTime":"0","endTime":"0","summary":"恒生生物科技指数盘中涨超1%，药明康德涨超5%，药明生物、京东健康、信达生物纷纷走强。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/02104750091629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1591","LU0039217434.USD","02359","LU0516423174.USD","LU0819121731.USD","LU0043850808.USD","LU0979878070.USD","IE00B0JY6N72.USD","LU0417516902.SGD","LU0516422366.SGD","LU0348735423.USD","LU1688375341.USD","LU2125910500.SGD","603259","BK1247","BK1583","86618","BK1576","BK1610","LU0348825331.USD","LU0417516738.SGD","LU0708995583.HKD","LU0516423091.SGD","LU2328871848.SGD","LU0327786744.USD","LU1242518931.SGD","LU1720050803.USD","02269","BK1515","LU1794554557.SGD","BK1521","LU0856984785.SGD","LU0326950275.SGD","BK0216","LU0516422952.EUR","LU0516422440.USD","LU0359201612.USD","LU0052750758.USD","LU2488822045.USD","LU1242518857.USD","LU1880383366.USD","LU2495084118.USD","01801","BK1615","LU2242644610.SGD","SG9999002562.SGD","06618","159892","LU1997245177.USD","LU0307460666.USD"],"gpt_icon":0},{"id":"2532375128","title":"智通港股早知道 | 终端设备直连卫星服务管理规定发布 蔚来-SW(09866)4月交付2.39万辆同比增长53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532375128","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532375128?lang=zh_cn&edition=full","pubTime":"2025-05-02 07:28","pubTimestamp":1746142107,"startTime":"0","endTime":"0","summary":"七部门联合发布《终端设备直连卫星服务管理规定》智通财经APP获悉，据国家互联网信息办公室4月30日消息，近日，国家互联网信息办公室等七部门联合发布《终端设备直连卫星服务管理规定》，自2025年6月1日起施行。提出终端设备直连卫星服务管理坚持发展和安全并重、促进创新和依法治理相结合的原则。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f3798be17a578f5a81e3aff63bc79920","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1604","HSCEI","LU0654597011.USD","BK4099","EVS.SI","LU1119994140.HKD","01801","LU0550127509.SGD","LU2328871848.SGD","BK1589","BK1196","01378","BK4532","LU2242652126.USD","LU0575583348.USD","BK1561","NIO.SI","BK4548","LU2092937221.SGD","LU2360108059.USD","LU0708995583.HKD","LU0997586606.USD","BK1500","LU0612318971.USD","HSTECH","LU1969619763.USD","LU2242646235.USD","LU1989763427.SGD","LU2488822045.USD","SW","BK4505","BK4504","00357","LU1166156734.SGD","LU1920063259.USD","NIO","LU0737861699.HKD","09866","LU1430597077.USD","LU1015430645.USD","YANG","LU2242646821.SGD","SG9999001093.SGD","LU1863844665.USD","BK4585","BK4581","LU0052750758.USD","LU0048578792.EUR","LU2041044095.USD"],"gpt_icon":1},{"id":"2532022948","title":"信达生物(01801)第一季度总产品收入超24亿元，同比保持40%以上的强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2532022948","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532022948?lang=zh_cn&edition=full","pubTime":"2025-05-01 18:05","pubTimestamp":1746093913,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，于2025年第一季度，公司共取得总产品收入超人民币24亿元，同比保持40%以上的强劲增长。其中：1)公司在肿瘤治疗领域已树立领导品牌，达伯舒 等主要产品保持快速的增长态势，新产品收入贡献加速提升;及2)综合产品线潜力逐渐释放，信必乐 新进入国家医保目录生效，信必敏 成功获批上市用于治疗甲状腺眼病，为增长贡献新驱动力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801","LU2328871848.SGD","LU1969619763.USD","BK1161","BK1589","LU2488822045.USD","BK1583"],"gpt_icon":0},{"id":"2532026583","title":"成交额超34亿，信达生物业绩引爆市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2532026583","media":"医药魔方Invest","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532026583?lang=zh_cn&edition=full","pubTime":"2025-04-30 17:45","pubTimestamp":1746006300,"startTime":"0","endTime":"0","summary":"在年报发出当天早盘竞价期间，信达生物盘面异动，成交量达4200万股，成交额达23亿元；全天成交量达6592万股，成交额达34.46亿元。2024年度，信达销售及市场推广开支为43.47亿元，占产品收入的52.8%，2023年度为31亿元，占产品收入的54.1%。2024年下半年，信达与驯鹿生物订立一系列合作协议。截至2024年12月31日止年度，信达已确认的授权费收入为6.9亿元，计入合约负债中的部分总代价将于日后确认为收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050116205994e9c8d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050116205994e9c8d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","BK1583","LU2328871848.SGD","LU1969619763.USD","LU2488822045.USD","BK1161","BK1589"],"gpt_icon":0},{"id":"2531294757","title":"信达生物全球首创双载荷ADC完成首例临床给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2531294757","media":"DoNews","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531294757?lang=zh_cn&edition=full","pubTime":"2025-04-30 11:21","pubTimestamp":1745983262,"startTime":"0","endTime":"0","summary":"信达生物宣布，其自主研发的全球首创靶向CEACAM5的双载荷ADC（IBI3020）在I期临床研究中完成首例受试者给药。作为信达生物自研ADC平台DuetTx的首个双载荷ADC产品，IBI3020也是全球同类型双载荷ADC中首个进入临床阶段的项目。该研究旨在评估IBI3020在晚期实体瘤患者中的安全性、耐受性及初步有效性，并为II期临床试验确定推荐剂量。这一进展标志着信达生物在创新肿瘤疗法领域取得重要突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043011221594e85e50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043011221594e85e50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","BK1589","01801","BK1583","LU1969619763.USD","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2531474115","title":"信达生物宣布全球首创CEACAM5 双载荷ADC（IBI3020）完成临床I期研究首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2531474115","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531474115?lang=zh_cn&edition=full","pubTime":"2025-04-30 08:00","pubTimestamp":1745971200,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州 2025年4月30日 /美通社/ --信达生物制药集团，一家致力于研发、生产和销售肿瘤、自免、代谢、眼科等重大疾病领域创新药物的生物制药公司，今日宣布其自主研发的全球首创靶向CEACAM5的双载荷ADC在I期临床研究中完成首例受试者给药。这是信达生物自研ADC平台DuetTx上产出的第一个双载荷ADC，也是已知全球范围内同类型双载荷中首个完成临床患者给药的双载荷ADC。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4675471_ZH75471_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4080","BK1583","BK1589","LU2488822045.USD","BK1161","LU2328871848.SGD","BK4231","LU1969619763.USD","01801","ADC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0455},{"period":"1month","weight":0.2417},{"period":"3month","weight":0.4455},{"period":"6month","weight":0.3488},{"period":"1year","weight":0.2922},{"period":"ytd","weight":0.4317}],"compareEarnings":[{"period":"1week","weight":0.0161},{"period":"1month","weight":0.1285},{"period":"3month","weight":0.0821},{"period":"6month","weight":0.1032},{"period":"1year","weight":0.2336},{"period":"ytd","weight":0.14}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.056031},{"month":2,"riseRate":0.714286,"avgChangeRate":0.11927},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.021767},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.285714,"avgChangeRate":0.002016},{"month":6,"riseRate":0.666667,"avgChangeRate":0.118103},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.029935},{"month":8,"riseRate":0.833333,"avgChangeRate":0.002206},{"month":9,"riseRate":0.666667,"avgChangeRate":0.03832},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.010418},{"month":11,"riseRate":0.571429,"avgChangeRate":0.078824},{"month":12,"riseRate":0.428571,"avgChangeRate":0.054557}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}